These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 33532919)

  • 1. The Cost-Effectiveness and Budget Impact of Ibalizumab-uiyk for Adults with Multidrug-Resistant HIV-1 Infection in the United States.
    Brogan AJ; Talbird SE; Davis AE; La EM; Kumar PN
    Pharmacoeconomics; 2021 Apr; 39(4):421-432. PubMed ID: 33532919
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical and Economic Impact of Ibalizumab for People With Multidrug-Resistant HIV in the United States.
    Millham LRI; Scott JA; Sax PE; Shebl FM; Reddy KP; Losina E; Walensky RP; Freedberg KA
    J Acquir Immune Defic Syndr; 2020 Feb; 83(2):148-156. PubMed ID: 31929403
    [TBL] [Abstract][Full Text] [Related]  

  • 3. US cost-utility model of lenacapavir plus optimized background regimen (OBR) vs fostemsavir plus OBR and ibalizumab plus OBR for people with HIV with multidrug resistance.
    Vardanega V; New E; Mezzio D; Eddowes LA
    J Manag Care Spec Pharm; 2024 Sep; 30(9):1001-1012. PubMed ID: 39213144
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ibalizumab, a Novel Monoclonal Antibody for the Management of Multidrug-Resistant HIV-1 Infection.
    Beccari MV; Mogle BT; Sidman EF; Mastro KA; Asiago-Reddy E; Kufel WD
    Antimicrob Agents Chemother; 2019 Jun; 63(6):. PubMed ID: 30885900
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of optimized background therapy plus maraviroc for previously treated patients with R5 HIV-1 infection from the perspective of the Spanish health care system.
    Moreno S; González J; Lekander I; Martí B; Oyagüez I; Sánchez-de la Rosa R; Casado MA
    Clin Ther; 2010 Dec; 32(13):2232-45. PubMed ID: 21316539
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness analysis of raltegravir in treatment-experienced HIV type 1-infected patients in Spain.
    Chaudhary MA; Moreno S; Kumar RN; Nocea G; Elbasha E
    AIDS Res Hum Retroviruses; 2009 Jul; 25(7):679-89. PubMed ID: 19552590
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ibalizumab: A Review in Multidrug-Resistant HIV-1 Infection.
    Blair HA
    Drugs; 2020 Feb; 80(2):189-196. PubMed ID: 31970712
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase 3 Study of Ibalizumab for Multidrug-Resistant HIV-1.
    Emu B; Fessel J; Schrader S; Kumar P; Richmond G; Win S; Weinheimer S; Marsolais C; Lewis S
    N Engl J Med; 2018 Aug; 379(7):645-654. PubMed ID: 30110589
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost effectiveness and budget impact of natalizumab in patients with relapsing multiple sclerosis.
    Chiao E; Meyer K
    Curr Med Res Opin; 2009 Jun; 25(6):1445-54. PubMed ID: 19422279
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ibalizumab for the treatment of multidrug-resistant HIV-1 infection.
    Rizza SA; Bhatia R; Zeuli J; Temesgen Z
    Drugs Today (Barc); 2019 Jan; 55(1):25-34. PubMed ID: 30740610
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of maraviroc for antiretroviral treatment-experienced HIV-infected individuals in Mexico.
    Contreras-Hernandez I; Becker D; Chancellor J; Kühne F; Mould-Quevedo J; Vega G; Marfatia S
    Value Health; 2010 Dec; 13(8):903-14. PubMed ID: 21091827
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative Efficacy and Safety of Fostemsavir in Heavily Treatment-Experienced People With HIV-1.
    Anderson SJ; van Doornewaard A; Turner M; Jacob I; Clark A; Browning D; Schroeder M
    Clin Ther; 2022 Jun; 44(6):886-900. PubMed ID: 35610081
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ibalizumab.
    Bettiker RL; Koren DE; Jacobson JM
    Curr Opin HIV AIDS; 2018 Jul; 13(4):354-358. PubMed ID: 29746266
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ibalizumab-uiyk as a bridge therapy for a patient with drug-resistant HIV-1 infection receiving chemotherapy: A case report.
    Dickter JK; Martin AL; Ho S; Ross JA; Shouse GP
    J Clin Pharm Ther; 2021 Aug; 46(4):1185-1187. PubMed ID: 34111306
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A microsimulation of the cost-effectiveness of maraviroc for antiretroviral treatment-experienced HIV-infected individuals.
    Kühne FC; Chancellor J; Mollon P; Myers DE; Louie M; Powderly WG
    HIV Clin Trials; 2010; 11(2):80-99. PubMed ID: 20542845
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of combination therapy with etravirine in treatment-experienced adults with HIV-1 infection.
    Mauskopf J; Brogan AJ; Talbird SE; Martin S
    AIDS; 2012 Jan; 26(3):355-64. PubMed ID: 22089378
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ibalizumab: First Global Approval.
    Markham A
    Drugs; 2018 May; 78(7):781-785. PubMed ID: 29675744
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expanded HIV screening in the United States: effect on clinical outcomes, HIV transmission, and costs.
    Paltiel AD; Walensky RP; Schackman BR; Seage GR; Mercincavage LM; Weinstein MC; Freedberg KA
    Ann Intern Med; 2006 Dec; 145(11):797-806. PubMed ID: 17146064
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
    Shepherd J; Jones J; Takeda A; Davidson P; Price A
    Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.